Cabozantinib, a multi-tyrosine kinase inhibitor, has been observed to induce p53 upregulated modulator of apoptosis (PUMA), a crucial pro-apoptotic protein, through the activation of the AKT/GSK-3β/NF-κB signaling pathway in CRC. Here, AKT1 is linked to colorectal carcinoma.